Voyager Therapeutics Inc., of Cambridge, Mass., reported interim surgical results from an ongoing phase Ib study of VY-AADC01 in patients with advanced Parkinson's disease at the International Congress of Parkinson's Disease and Movement Disorders in Berlin. Read More
Aytu Bioscience Inc., of Englewood, Colo., said it plans a 1-for-12 reverse split of its outstanding common shares, effective following the market close on June 30. Read More
Paratek Pharmaceuticals Inc., of Boston, priced an underwritten public offering of 4.25 million common shares at $13 apiece, a 2 percent discount to Tuesday's closing price of $13.28 for the company's shares (NASDAQ:PRTK), and granted underwriters a 30-day option to purchase up to 637,500 additional shares to fill overallotments. Read More
IFM Therapeutics Inc. closed a $27 million series A financing led by Atlas Venture and Abingworth, with participation from Novartis AG. The Cambridge, Mass.-based company, incubated at Atlas, will use the financing to advance and expand its early stage portfolio of preclinical small-molecule modulators. Read More
It seems pretty dire. As News Editor Marie Powers wrote in yesterday's edition, " . . . the cupboard of innovative treatments to address these pathogens is meager and the supply of scientists needed to restock the shelves is scarce." Read More
As interest builds in the field of bispecific antibodies, one-year-old China-based Epimab Biotherapeutics Inc. is preparing for a series A financing and just announced its first licensing deal for the company's flagship technology platform, FIT-Ig – or Fabs-In-Tandem. Read More
BOGOTA, Colombia – A Brazilian pharma company based in Itapira, Sao Paulo, has obtained the very first biodiversity-based registration from Anvisa of a biological active pharmaceutical ingredient (API). Cristália's API is an enzyme called collagenase Cristalia, used in ointments to treat wounds, burns and necrotic tissue. To date, Brazil has had to rely on imports of collagenase. Read More
Academia's role in antibiotic development – crucial since the dawn of the antibiotic age when Oxford University purified penicillin ahead of mass production – remains just as important today. Despite the centrality of pioneering work undertaken at universities, challenges from basic training to funding crunches have left a yawning gap in some areas, contributing to a complex web of problems slowing the arrival of new antibiotics on the market. Read More
It's all hands on deck when it comes to fighting superbugs in the U.S. Not only are multiple state and federal agencies involved, they're using every regulatory weapon at their disposal in the battle against the emergence of nightmare bacteria. Read More
